Amit Munshi Buys 159,744 Shares of Zura Bio Limited (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) Director Amit Munshi bought 159,744 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was bought at an average price of $3.13 per share, with a total value of $499,998.72. Following the acquisition, the director now owns 777,384 shares in the company, valued at approximately $2,433,211.92. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Zura Bio Price Performance

Shares of ZURA stock opened at $3.62 on Friday. Zura Bio Limited has a 52-week low of $2.00 and a 52-week high of $14.00. The stock has a 50 day moving average price of $3.19 and a 200 day moving average price of $4.03.

Institutional Investors Weigh In On Zura Bio

A number of institutional investors and hedge funds have recently modified their holdings of ZURA. Armistice Capital LLC lifted its stake in shares of Zura Bio by 66.3% during the 3rd quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock worth $10,428,000 after acquiring an additional 630,000 shares during the last quarter. Silverarc Capital Management LLC lifted its stake in shares of Zura Bio by 152.5% during the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after acquiring an additional 244,040 shares during the last quarter. Eisler Capital US LLC bought a new stake in shares of Zura Bio during the 3rd quarter worth approximately $660,000. Bank of New York Mellon Corp bought a new stake in shares of Zura Bio during the 3rd quarter worth approximately $224,000. Finally, Forefront Analytics LLC bought a new stake in shares of Zura Bio during the 3rd quarter worth approximately $95,000. 61.14% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, Oppenheimer reiterated an “outperform” rating and issued a $16.00 target price (down previously from $17.00) on shares of Zura Bio in a report on Monday, April 1st. Four analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $16.40.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.